AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02271945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0680 10 mg/kg
Description: Participants will receive IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
Study NCT01940536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: antifibrinolytic
Study NCT01940536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00256516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eco-Atkins diet (high vegetable protein and vegetable fat)
Study NCT01184105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention A
Description: A single dose of 60 mg will consist of 6 sprays of the 10 mg strength spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
Study NCT01184105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention B
Description: A dose of placebo will consist of 6 sprays of the placebo spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
Study NCT02131402 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ocufilcon D
Description: Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (ocufilcon D) in the contra lateral eye.
Study NCT02131402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A
Description: Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (omafilcon A) in the contra lateral eye.
Study NCT02131402 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: methafilcon A
Description: Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (methafilcon A) in the contra lateral eye.
Study NCT01536379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab (10 mg/kg) will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
Study NCT01536379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
Study NCT00006079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine
Description: Arm I-II: Patients receive one of two different doses of oral eflornithine daily for 28 days.
Study NCT02836899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
Study NCT04189601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Complement measurements
Description: Blood and urine tests to assess the complement activation state
Study NCT03440125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cayenne Pepper topical
Description: 20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water
Study NCT03440125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Electrical stimulation 10min 60Hz biphasic rectangular neuromuscular electrical Stimulation (NMES)
Study NCT03440125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage
Description: 10 minutes of classical massage of low back pain area.
Study NCT00006079 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive oral placebo daily for 28 days.
Study NCT00777309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: 360 mg administered twice daily until disease progression, unacceptable toxicity or other discontinuation criterion is met
Study NCT00256516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCEP diet
Study NCT00597493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib and Temozolomide
Description: Temozolomide (50 mg per meter-squared of body surface area)every day by mouth in combination with sorafenib. Sorafenib will be taken by mouth twice every day. The dose of sorafenib will be 400 mg (2 x 200mg tablets).
Study NCT03846557 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: Implantation of the Acurate Neo Transcatheter Heart Valve
Study NCT01854268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Healthy adults who receive capsaicin
Description: Participants will be seated in a comfortable chair and fitted with cotton elastic bands designed to measure changes in chest wall and abdominal movement during cough. The participant will hold a facemask attached to a pneumotachograph, nebulized, and dosimeter. The participant will receive 3 nebulized doses of 200 microMolar capsaicin through the facemask. The participants will have a minute in between each presentation and water will be available at all times.
Study NCT00978874 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Study NCT00978874 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 EF5
Study NCT03545542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Initial fecal microbiome
Description: Stool sampling for fecal microbiome analysis by 16S rDNA pyrosequencing. Neuroblastoma group and Control group.
Study NCT02836899 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the placebo group. Nitrogen will be added instead of nitric oxide.
Study NCT00777309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib is a white, film coated tablet in strengths of 25, 100 and 150 mg administered once daily until disease progression, unacceptable toxicity or other discontinuation criterion is met.
Study NCT00777309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib is a white, film coated tablet in strengths of 25, 100 and 150 mg administered once daily until disease progression, unacceptable toxicity or other discontinuation criterion is met.
Study NCT00777309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo is provided as a capsule
Study NCT01867086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil™ Vaccine
Description: Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 3 weeks.
Study NCT01867086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatinum
Description: Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
Study NCT01867086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatinum and Taxol
Description: Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
Study NCT03792568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALK Inhibitor
Description: Any ALK inhibitor like crizotinib, alectinib and so on.
Study NCT02180841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy Protein Powder (25g/d)
Description: Participants will consume 25g soy protein powder daily for a 6 week treatment period.
Study NCT02180841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Powder (25g/d)
Description: Participants will consume 25g soy protein powder daily for a 6 week treatment period.
Study NCT02180841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume a placebo control powder containing 0g soy protein powder daily for a 6 week treatment period.
Study NCT02180841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will consume a placebo control powder containing 0g soy protein powder daily for a 6 week treatment period.
Study NCT03545542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Initial fecal microbiome
Description: Stool sampling for fecal microbiome analysis by 16S rDNA pyrosequencing. Neuroblastoma group and Control group.
Study NCT03545542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Initial fecal volatile organic compounds
Description: Volatile organic compound analysis of stool samples by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
Study NCT01272609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol + LCP
Description: Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
Study NCT01272609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LCP
Description: Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ²if LCP of Cynosure © spaced out of 1 month.
Study NCT01984008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picosulfate sodium, magnesium oxide, citric acid
Study NCT01984008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Picosulfate sodium, magnesium oxide, citric acid
Study NCT00813085 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electronic disease management decision support
Description: A Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS)
Study NCT03343041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low-carbohydrate nutrition
Description: low-carbohydrate enteral nutrition
Study NCT03343041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard enteral nutrition
Description: standard enteral nutrition
Study NCT02180841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy Protein Powder (50g/d)
Description: Participants will consume 50g soy protein powder daily for a 6 week treatment period.
Study NCT02180841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Powder (50g/d)
Description: Participants will consume 50g soy protein powder daily for a 6 week treatment period.
Study NCT04541511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minutes walking test on a corridor
Description: 6-minutes walking test on a corridor : patient will be asked to achieve the longest possible distance without running. He/she will be allowed to take breaks if he/she feels the need to do so.
Study NCT04541511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minutes walking test on a treadmill
Description: 6-minutes walking test on a treadmill : patient will be asked to achieve the longest possible distance without running on the treadmill. He/she will be allowed to take breaks if he/she feels the need to do so.
Study NCT02504307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus Eluting Stent Inspiron
Description: Angioplasty with Sirolimus Eluting Stent Inspiron implantation
Study NCT02504307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare Metal Stent
Description: Angioplasty with Bare Metal Stent Cronus implantation
Study NCT00732108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 50mg orally for 2 weeks, then 100mg orally for 6 weeks
Study NCT00732108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactulose placebo pill
Description: 1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
Study NCT03545542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Initial fecal volatile organic compounds
Description: Volatile organic compound analysis of stool samples by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
Study NCT03545542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Initial breath volatile organic compounds
Description: Breath sampling for organic compound analysis by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
Study NCT03545542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Initial breath volatile organic compounds
Description: Breath sampling for organic compound analysis by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
Study NCT03545542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microbiome under chemotherapy
Description: Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to Société Internationale d´Onclogie Pediatrique Neuroblastoma Group (SIOPEN) guidelines
Study NCT03545542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fecal volatile organic compounds under chemotherapy
Description: Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group
Study NCT03545542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breath volatile organic compounds under chemotherapy
Description: Breath sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group
Study NCT03545542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Final microbiome
Description: Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
Study NCT03545542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Final fecal volatile organic compounds
Description: Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
Study NCT03545542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Final breath volatile organic compounds
Description: Breath sampling 3 weeks after completion of chemotherapy Neuroblastoma group
Study NCT00802893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6R-BH4
Description: 6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period
Study NCT00802893 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo given BID for entire length of study
Study NCT02868229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COR-001
Study NCT02868229 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01113580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL's 2010/2011 Formulation of Enzira® Vaccine
Description: 45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0
Study NCT03527524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise with ball
Description: exercise with ball
Study NCT03527524 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise without ball
Description: exercise without ball
Study NCT02961946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.
Study NCT01778803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defactinib
Study NCT01778803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT03094442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: An 8 mg dose of Dexamethasone is administered at the time of induction of general anesthesia. The medication is provided by the pharmacy in a blinded syringe.
Study NCT03094442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
Study NCT03853941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Theory-based communication training programme delivered to healthcare professionals
Study NCT02488733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LSG
Description: In addition to all previously described aspects of conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines
Study NCT02488733 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CMT
Description: CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)\[50\] and determined on an individual basis \[52\].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .
Study NCT02488733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMT
Description: CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)\[50\] and determined on an individual basis \[52\].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .
Study NCT01985256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511
Description: All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene, intravenously and then intracranially. CD converts the antifungal 5-fluorocytosine (5-FC) to the anti-cancer drug 5-fluorouracil (5-FU) in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after the second administration of Toca 511,patients will begin 7-day course of oral 5-FC, repeated every 4 weeks for the duration of the study.
Study NCT01985256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC
Study NCT02834559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil and low molecular weight heparin
Description: Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).
Study NCT02834559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV).
Study NCT05737927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose 16 g coated beads (47% w/w)
Description: After an overnight fasting of about 10 hours, the subjects were administered 16 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
Study NCT00759408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123
Description: 6-120 µg/min
Study NCT05737927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose 12 g uncoated beads
Description: After an overnight fasting of about 10 hours, the subjects were administered the uncoated Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.